XEN gel stent: Definition, Uses, and Clinical Overview

XEN gel stent Introduction (What it is)

XEN gel stent is a tiny implanted tube used in glaucoma care to help lower eye pressure.
It creates a new pathway for fluid to drain from inside the eye to the outer eye tissues.
It is most commonly discussed within minimally invasive glaucoma surgery (MIGS).
It is typically used by glaucoma specialists in an operating room or surgical center setting.

Why XEN gel stent used (Purpose / benefits)

Glaucoma is a group of eye diseases in which the optic nerve can be damaged over time, often (but not always) in the setting of elevated intraocular pressure (IOP). When IOP is higher than the eye can tolerate, lowering that pressure is a central goal of treatment because it can reduce the risk of further optic nerve injury.

XEN gel stent is used to lower IOP by improving the eye’s fluid outflow. The eye continuously produces a clear fluid called aqueous humor, and pressure rises when outflow is reduced. Many glaucoma treatments aim to either decrease fluid production (medications, some laser procedures) or increase fluid drainage (laser or surgery). XEN gel stent falls into the “increase drainage” category.

In broad terms, potential benefits include:

• Providing an additional option when eye drops and/or laser treatments do not achieve target IOP (the pressure goal set by a clinician based on optic nerve status and other factors).
• Offering a less tissue-disruptive approach than some traditional filtering surgeries in selected patients, while still aiming to achieve meaningful IOP reduction.
• Reducing IOP fluctuation in some cases, which may be relevant in glaucoma management (how much this occurs varies by clinician and case).
• Potentially reducing dependence on glaucoma medications for some patients, although ongoing drops may still be needed depending on the eye and disease stage.

Indications (When ophthalmologists or optometrists use it)

Typical scenarios where XEN gel stent may be considered include:

• Open-angle glaucoma with IOP that remains above target despite medications and/or laser therapy.
• Cases where medication burden is high (multiple drops) and a procedure-based IOP-lowering approach is being considered.
• Patients who are not ideal candidates for certain angle-based MIGS due to severity of glaucoma or pressure goals (selection varies by clinician and case).
• Some secondary glaucomas where lowering IOP via an alternate outflow pathway is desired (suitability varies by cause).
• Situations where a surgeon is considering a filtering-type procedure but wants an approach that uses a small implant rather than creating a surgical flap (choice varies by clinician and case).
• Standalone glaucoma surgery or combined planning with cataract surgery in certain cases (approach varies by surgeon and eye anatomy).

Note: Optometrists commonly identify glaucoma, monitor disease, and co-manage care, but implantation is performed by an ophthalmologist (often a glaucoma specialist).

Contraindications / when it’s NOT ideal

XEN gel stent may be less suitable, or a different approach may be preferred, in situations such as:

• Angle-closure glaucoma that is not adequately opened or is anatomically unsuitable for the intended placement approach.
• Active eye infection or significant ocular surface inflammation that could increase postoperative risk.
• Conjunctival scarring (for example from prior surgery, injury, or inflammation) in the area needed for drainage, which may limit bleb formation or function.
• Eyes with a higher risk of scarring response (risk level varies by individual factors), where alternative procedures may be chosen based on surgeon judgment.
• Eyes requiring very low target pressures that may be more consistently achieved with other filtering surgeries in some hands (varies by clinician and case).
• Situations where the patient cannot reliably attend follow-up visits; postoperative monitoring is a major part of filtering-style glaucoma procedures.
• Allergies or contraindications to adjunctive medications sometimes used around the time of surgery (varies by medication and manufacturer), when alternatives are not appropriate.

Contraindications are not always absolute. Surgeons often weigh anatomy, glaucoma severity, past surgeries, and risk tolerance when choosing between surgical options.

How it works (Mechanism / physiology)

Mechanism of action (high level)

XEN gel stent works by creating a controlled outflow channel for aqueous humor from the anterior chamber (the fluid-filled space between the cornea and the iris) to the subconjunctival space (the tissue layer under the conjunctiva, the thin membrane covering the white of the eye). The drained fluid collects under the conjunctiva in a small elevation called a bleb, where it can then be absorbed by surrounding tissues.

This is a “filtering” concept: rather than improving the eye’s natural trabecular outflow pathway, it provides an alternate drainage route.

Relevant anatomy and tissues

Key structures involved include:

• Anterior chamber: where aqueous humor circulates.
• Trabecular meshwork/angle structures: the natural outflow region (not the primary drainage route used by the stent, but relevant to glaucoma type and anatomy).
• Sclera and conjunctiva: outer eye layers through which/under which fluid is redirected.
• Subconjunctival space: where a bleb forms and regulates outflow through tissue resistance and healing response.

Onset, duration, and reversibility

• Onset: IOP lowering is generally expected soon after surgery, but the early postoperative period can be variable because tissue healing and inflammation influence flow and bleb formation.
• Duration: The implant is intended to remain in place long term. Long-term effectiveness depends heavily on wound healing and scarring, which can reduce drainage over time.
• Reversibility: This is not a temporary treatment like an eye drop. While implants can sometimes be revised or removed, the procedure is best understood as a surgical intervention with lasting tissue effects (degree varies by clinician and case).

XEN gel stent Procedure overview (How it’s applied)

XEN gel stent is a surgical implant procedure performed by an ophthalmologist. Exact techniques differ by surgeon, training, and patient anatomy, but a typical workflow includes:

1. Evaluation/exam
   The clinician confirms the glaucoma type and severity and reviews IOP history, optic nerve status, visual field testing, and current medications. Anatomy is assessed at the slit lamp and often with gonioscopy (a lens-based exam of the eye’s drainage angle).

2. Preparation and planning
   The surgical plan considers prior eye surgeries, conjunctival health, and target IOP. Medication adjustments around surgery vary by clinician and case. The role of adjunctive anti-scarring medication is also planned (choice and concentration vary by clinician and material/manufacturer).

3. Anesthesia and sterile setup
   The procedure is commonly performed under local anesthesia with antiseptic preparation. Patient comfort measures vary by setting.

4. Implant placement (intervention)
   The stent is inserted to create a pathway from inside the eye to the subconjunctival space. Surgeons may use an “inside-out” (ab interno) approach and, in some practices, an “outside-in” (ab externo) approach, depending on preference and eye factors.

5. Immediate checks
   The surgeon checks implant position, confirms appropriate fluid flow, and assesses the early bleb appearance. The eye is examined for pressure level and signs of bleeding or inflammation.

6. Follow-up visits
   Postoperative visits are used to monitor IOP, bleb function, inflammation, and healing. Some cases require bleb management, which may include office-based interventions such as “needling” (a technique to reduce scar tissue around the bleb) when clinically appropriate.

This overview is intentionally general; surgical steps and postoperative protocols are individualized.

Types / variations

Common clinically discussed variations related to XEN gel stent include:

• Different model specifications
  The most widely referenced model in many settings is XEN45 (often named for its internal lumen size). Other versions have existed or been discussed in the field; availability varies by region, regulatory status, and manufacturer.

• Standalone vs combined procedures
  XEN gel stent may be implanted as a standalone glaucoma surgery or at the same time as cataract surgery in selected patients. Whether combining procedures is appropriate depends on lens status, glaucoma goals, and surgical planning.

• Ab interno vs ab externo technique
  Some surgeons implant from inside the eye (ab interno), while others may use an external approach (ab externo). The goal is the same—subconjunctival filtration—but the tissue handling and visualization differ.

• Adjunctive anti-scarring strategies
  Many filtering-type glaucoma procedures incorporate medications or techniques intended to reduce subconjunctival scarring. Specific agents and dosing protocols vary by clinician and case.

Pros and cons

Pros:

• Can lower intraocular pressure by creating an alternate drainage pathway.
• Fits within the MIGS spectrum for selected patients, often with smaller incisions than traditional filtering surgeries.
• May reduce medication burden for some patients (results vary by clinician and case).
• Uses a standardized implant that may offer procedural consistency in trained hands.
• Can be considered in eyes where angle-based MIGS may not meet the desired pressure target (varies by case).
• May be performed as a standalone procedure or combined with cataract surgery in selected situations.

Cons:

• Effectiveness can be limited by postoperative scarring and bleb healing response.
• Requires close follow-up; bleb management (including possible needling) may be part of care.
• Risks include low IOP (hypotony), bleeding, inflammation, implant malposition or blockage, and infection (including bleb-related infection), among others.
• Some patients still need glaucoma drops after surgery, depending on target IOP and disease severity.
• Outcomes can be less predictable than purely medication-based management because wound healing varies between individuals.
• Not ideal for every glaucoma type or eye anatomy (for example, significant conjunctival scarring may reduce success).

Aftercare & longevity

Aftercare for a filtering-style procedure like XEN gel stent is centered on monitoring healing and maintaining a functioning bleb. The early postoperative period is especially important because inflammation and scar tissue formation can change drainage and IOP.

Longevity is influenced by several interacting factors:

• Wound healing and scarring response: Some eyes form scar tissue more aggressively, which can restrict fluid flow under the conjunctiva.
• Severity and type of glaucoma: Advanced disease may require lower target IOPs, which can influence whether additional treatments are needed.
• Adherence to follow-up: Scheduled visits allow clinicians to detect pressure changes early and manage bleb function when needed.
• Ocular surface health: Dry eye disease, blepharitis, and chronic surface inflammation can complicate comfort and healing (impact varies).
• Prior surgeries and conjunctival status: Existing scarring can limit bleb formation and affect long-term function.
• Device positioning and patency: Blockage or malposition can reduce effectiveness; how often this occurs varies by clinician and case.

In general terms, some patients experience stable IOP control for extended periods, while others may need additional medications, office-based bleb interventions, laser procedures, or further glaucoma surgery over time. The implant itself is designed to remain in the eye, but long-term results depend more on tissue behavior than on the device alone.

Alternatives / comparisons

Choosing among glaucoma treatments is typically a stepwise process that balances disease severity, target IOP, risk tolerance, and lifestyle considerations. XEN gel stent is one option within a broader landscape.

Common alternatives and how they compare at a high level:

• Observation/monitoring (when appropriate)
  In glaucoma suspects or very early disease, clinicians may monitor optic nerve structure, visual fields, and IOP over time. This is not a pressure-lowering treatment but can be part of a careful diagnostic and management plan.

• Prescription eye drops
  Medications can lower IOP by decreasing aqueous production or increasing outflow through existing pathways. Drops avoid surgery but require consistent use and can cause side effects such as redness, irritation, or systemic effects in susceptible individuals.

• Laser trabeculoplasty (for open-angle glaucoma)
  Selective laser trabeculoplasty (SLT) is commonly used to improve trabecular outflow and can be considered before or after drops. It is office-based and repeatability varies by clinician and case.

• Angle-based MIGS (trabecular bypass or tissue removal procedures)
  Examples include trabecular micro-bypass stents and goniotomy-based procedures. These generally work through the eye’s natural drainage system and are often paired with cataract surgery. They may have a different risk/benefit profile than subconjunctival filtering approaches and may not achieve the same pressure goals in all cases (varies by case).

• Trabeculectomy (traditional filtering surgery)
  This surgery creates a guarded drainage pathway to form a bleb and can achieve very low pressures in some cases. It is more invasive than many MIGS approaches and typically requires intensive postoperative management.

• Glaucoma drainage devices (tube shunts)
  Tube implants route fluid to a plate where it is absorbed. These are often considered in more complex or refractory glaucomas, including eyes with significant prior surgery, though selection varies by surgeon.

• Cyclodestructive procedures (laser or other energy to reduce aqueous production)
  Procedures targeting the ciliary body can reduce fluid production. They may be considered in certain scenarios and have their own risk considerations.

In simplified terms: XEN gel stent is often positioned between “less invasive” angle-based options and “more traditional” filtering/tube surgeries, but the best match depends on the individual eye and clinician goals.

XEN gel stent Common questions (FAQ)

Q: Is XEN gel stent a glaucoma cure?
No. Glaucoma is generally considered a chronic condition that requires ongoing monitoring. The purpose of XEN gel stent is to lower eye pressure to help slow or reduce the risk of further optic nerve damage. Follow-up testing is still needed after any glaucoma procedure.

Q: Does the procedure hurt?
Most procedures are performed with anesthesia to reduce pain during surgery. Some irritation, scratchiness, or soreness can occur afterward, especially while the eye is healing. Comfort and recovery experiences vary by clinician and case.

Q: How long does it take to recover?
Many people resume routine activities gradually, but vision and comfort can fluctuate during early healing. The timeline depends on inflammation, pressure stability, and whether bleb management is needed. Your clinician’s postoperative schedule reflects the need for close monitoring rather than a one-size-fits-all recovery window.

Q: Will I still need glaucoma drops after XEN gel stent?
Some patients can reduce the number of medications, while others still require drops to reach target IOP. Needing fewer drops is a common goal, but not a guaranteed outcome. The answer depends on glaucoma severity, baseline IOP, and healing response.

Q: How long do the results last?
The implant is designed to remain in place long term, but the pressure-lowering effect can change over time. Scarring around the bleb is a major factor that can reduce drainage. Longevity varies by clinician and case, and some eyes need additional interventions later.

Q: What are the main risks people should know about?
Risks can include low IOP, bleeding, inflammation, implant blockage or malposition, and infection. Because this is a bleb-forming procedure, bleb-related issues (such as leakage or infection) are also part of the risk discussion. Individual risk depends on eye anatomy, prior surgeries, and overall health factors.

Q: Is it safe to drive or use screens after the procedure?
Visual clarity can be temporarily affected by inflammation, medication effects, or changes in eye pressure. Screen use is often limited more by comfort (dryness, light sensitivity) than by safety, but experiences differ. Decisions about driving are typically based on how clearly you can see and what your care team advises for your situation.

Q: Why do some patients need “needling” after XEN gel stent?
Needling is an office-based technique used to address scar tissue that can form around the bleb and restrict flow. It is not unusual in bleb-based glaucoma procedures and may be part of maintaining long-term function. Whether it is needed depends on healing patterns and bleb appearance.

Q: How much does XEN gel stent cost?
Cost varies widely by country, insurance coverage, facility fees, and whether it is combined with cataract surgery. There may be separate costs for the device, surgeon, anesthesia, and postoperative care. A clinic or hospital billing team is usually best positioned to explain expected charges in a specific setting.